Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice
| Autor: | Juan Vicente-Valor, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Sara Pérez-Ramírez, Cristina Villanueva-Bueno, Álvaro Narrillos-Moraza, Sebastián García-Sánchez, Manel Beamud-Cortés, Ana Herranz, María Sanjurjo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY r-FISABIO. Repositorio Institucional de Producción Científica instname |
| ISSN: | 1744-7607 1742-5255 |
| Popis: | Background Abiraterone and enzalutamide, androgen receptor pathway inhibitors (ARPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), are at high risk of potential drug interactions (PDIs). We aimed to describe PDIs and their management, and triggered adverse events (AEs) in clinical practice. Methods We conducted a cross-sectional study in mCRPC patients who started treatment with abiraterone or enzalutamide in a university hospital between August 1st, 2016 and July 31st, 2020. Lexicomp (R) was used to identify and analyze PDIs, and the clinical records to assess their management and the occurrence of AEs. Results We included 173 patients: 36.8% and 93.0% treated with abiraterone and enzalutamide, respectively, had at least 1 PDI. Globally, 6.3% of PDIs had X-risk (contraindication due to high probability of AE). Treatment was modified in 9.2% of patients and 9.8% suffered AEs due to PDIs. Factors associated with a higher risk of PDIs were polypharmacy (OR= 41.0, p 0.003) and treatment with enzalutamide (OR= 128.26, p < 0.001). Conclusions At least two-thirds of patients treated with ARPI suffered a PDI. Overall, abiraterone would have a more favorable PDI profile. Knowing these interaction profiles may be helpful to develop a more efficient therapeutic follow-up and to select the safest treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|